<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370825</url>
  </required_header>
  <id_info>
    <org_study_id>KAMRC0601</org_study_id>
    <nct_id>NCT00370825</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy for the Treatment of Indian Kala-Azar</brief_title>
  <official_title>Combination Chemotherapy for the Treatment of Indian Visceral Leishmaniasis: Miltefosine Plus Liposomal Amphotericin B - Dose and Duration Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banaras Hindu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banaras Hindu University</source>
  <brief_summary>
    <textblock>
      The investigators are using a sequential design to combine miltefosine and AmBisome in&#xD;
      different doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this sequential design four arm study one arm is a reference arm but the three arms will&#xD;
      consist an of initial dose of liposomal amphotericin B on first day followed by miltefosine.&#xD;
      Both the drugs will be used in different doses. Reference arm will consist only a single dose&#xD;
      of amBisome at 5 mg/kg. After the end of treatment, the post treatment assessment will be&#xD;
      done on day 16 (initial cure) and six months (final cure). Safety parameters will be&#xD;
      evaluated on day 0, 8 and 16. An arm with an efficacy of less than 75% will be closed. There&#xD;
      will be periodical assessment of study results after completion of 5 patients in each arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of clinical kala-azar at six month follow up</measure>
  </primary_outcome>
  <enrollment>200</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination therapy with AmBisome and miltefosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of active VL with consistent signs and symptoms (e.g., fever,&#xD;
             splenomegaly).&#xD;
&#xD;
          -  Confirmed diagnosis by bone-marrow or splenic aspirate smear showing characteristic&#xD;
             amastigotes.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  Ages 12 to 65 years.&#xD;
&#xD;
          -  Both newly diagnosed cases and patients who have received previous treatment (in the&#xD;
             latter case a 2-week wash-out will be required before starting the study treatment).&#xD;
&#xD;
          -  WBC &gt; 1,000/mm3.&#xD;
&#xD;
          -  Hemoglobin ≥ 4 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  HIV positive serology.&#xD;
&#xD;
          -  ASAT, ALAT, AP ≥ 3 times upper limit of normal range.&#xD;
&#xD;
          -  Bilirubin ≥ 2 times upper limit of normal range.&#xD;
&#xD;
          -  Prothrombin time ≥ 5 seconds above control.&#xD;
&#xD;
          -  Serum creatinine or BUN ≥ 1.5 times upper limit of normal range.&#xD;
&#xD;
          -  Any medical condition or situation that compromises compliance with study procedures.&#xD;
&#xD;
          -  HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Shyam Sundar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Banaras Hindu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kala-azar Medical Research Center</name>
      <address>
        <city>Muzaffarpur</city>
        <state>Bihar</state>
        <zip>842001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>August 31, 2006</study_first_submitted>
  <study_first_submitted_qc>August 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2006</study_first_posted>
  <last_update_submitted>September 11, 2008</last_update_submitted>
  <last_update_submitted_qc>September 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2008</last_update_posted>
  <keyword>Visceral leishmaniasis</keyword>
  <keyword>miltefosine</keyword>
  <keyword>AmBisome</keyword>
  <keyword>Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Miltefosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

